SCHEMBL1153986

SCHEMBL1153986

Cc1ccc(C(O)(c2ccc(C)cc2)[C@@H](CC(C)C)NC(=O)C2(C(=O)N[C@H](CC(C)C)C(O)(c3ccc(C)cc3)c3ccc(C)cc3)CC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.40
HPGD P15428 3/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34
PSMB11 A5LHX3 2/20 0.34
PSMA7 O14818 2/20 0.34
PSMB1 P20618 2/20 0.34
PSMA1 P25786 2/20 0.34
PSMA2 P25787 2/20 0.34
PSMA3 P25788 2/20 0.34
PSMA4 P25789 2/20 0.34
PSMB8 P28062 2/20 0.34
PSMB9 P28065 2/20 0.34
PSMA5 P28066 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1153012 0.95 ANPEP (0.39) ANPEPHPGDSLC6A2SLC6A4SLC6A3
SCHEMBL1153589 0.95 ANPEP (0.39) ANPEPHPGDSLC6A2SLC6A4SLC6A3
SCHEMBL1152996 0.94 ANPEP (0.38) ANPEPHPGDSLC6A2SLC6A4SLC6A3
SCHEMBL1153439 0.88 CTSL (0.41) ANPEPPSMB8PSMB5ALDH1A1CYP2D6
SCHEMBL1153709 0.86 ANPEP (0.44) ANPEPNPC1RAB9AMEN1KMT2A
SCHEMBL1153715 0.83 HPGD (0.36) ANPEPHPGDNPC1MAPTRAB9A
SCHEMBL4343680 0.83 ANPEP (0.40) ANPEPHPGDSLC6A2SLC6A4SLC6A3
SCHEMBL1153629 0.83 CTSL (0.40) ANPEPALDH1A1CYP1A2CYP2D6CYP2C19
SCHEMBL1152498 0.83 PSEN1 (0.41) ANPEPHPGDALDH1A1CYP2D6CYP2C19
SCHEMBL1152877 0.82 ATM (0.46) NPC1MAPTRAB9APSMB8PSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943799-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-17 US disclosed
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-02-24 US disclosed
US-7842839-B2 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-30 US disclosed
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-17 US disclosed
EP-1698617-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENE BISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112201-A1 Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof CYP3A7, GRK7, CYP2A7 ANPEP 2755/4885HPGD 4153/4885SLC6A2 4608/4885
US-20110046415-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF CYP3A7, GRK7, CYP2A7 ANPEP 2755/4885HPGD 4153/4885SLC6A2 4608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.